ABT vs AMAL · P/E 25, rev $44.33B vs P/E 9.8, rev $226.5M
Abbott Laboratories (ABT) versus Amalgamated Bank (AMAL) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Amalgamated Bank (AMAL) is a banks - regional company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported AMAL revenue for 2026-06-30 was $226.5M. Net income was $60.0M. AMAL currently screens at market cap $1.02B and trailing P/E 9.8.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. AMAL currently screens at market cap $1.02B and trailing P/E 9.8.
Not investment advice. Open the ABT and AMAL stock pages for the full models.
Not investment advice.